Faced with the Ebola outbreak, researchers are stepping up their efforts to develop an effective vaccine. A first experimental test against the virus, dubbed ChAd3, was the subject of a clinical trial in the United States. According to early results, published on Wednesday, November 26, it is attributed the status of “promising.” The vaccine was well tolerated and triggered a good immune response in individuals tested.
“We are continuing our accelerated efforts to conduct trials with a larger number of people to establish its effectiveness in preventing infection with Ebola virus,” said on Wednesday Dr Anthony Fauci, director of the Institute of Allergy and infectious Diseases (NIAID).
Tested on 20 volunteers
NIAID explains that they consider conducting clinical trials called phase 2 and 3 in West Africa in 2015, stating to have had advanced discussions with leaders of Liberia and other countries on this subject. The vaccine has been tested with 20 volunteers in good health aged 18 to 50 years in clinical National Institutes of Health (NIH), which includes the NIAID.
It contains genetic elements from two strains of Ebola virus (Sudan and Zaire) that are routed adenovirus responsible for cold in chimpanzees, a harmless agent for humans. The vaccine did not cause serious side effects. Only two participants among those who received the highest dose had a brief fever.
According to a latest report from the World Health Organization (WHO), the Ebola virus has killed 5,689 people, mostly in West Africa, out of a total of nearly 15,935 infected patients.